Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Want to see VVOS full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.55Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call highlighted very strong top-line momentum—70% year-over-year revenue growth, 34% sequential growth, a 10 percentage-point gross margin improvement and rapidly rising patient volumes and KPIs driven by the SCN acquisition and provider productivity gains. However, these operational gains were offset by substantial increases in G&A and cash burn, a low cash balance (~$2.1M), increased discounts reducing product revenue, and an explicit need for additional financing and debt restructuring. Management presented multiple high-margin initiatives (pediatrics, insomnia services, medical affiliations) that could materially improve profitability, but near-term execution and capital availability remain material risks.Company Guidance
Strong Revenue Growth (YoY and QoQ)
Total revenue increased to $5.1 million in Q1 2026, a rise of approximately $2.1 million or ~70% year-over-year versus $3.0 million in Q1 2025, and a 34% increase compared to Q4 2025.
Diagnostic and Treatment Revenue Lift from SCN
Revenue benefited from the Sleep Center of Nevada (SCN) acquisition with an ~ $2.0 million increase in sleep testing services and ~$900,000 of new revenue from Vivos treatment of OSA patients launched at 2 SCN locations.
Higher Gross Profit and Improved Gross Margin
Gross profit rose $1.5 million or 103% to $3.1 million in Q1 2026. Gross margin expanded by 10 percentage points to 60% (from 50% in Q1 2025), reflecting the higher-margin nature of the new business model.
Material Increase in Patient Volume and Key Clinical KPIs
Total completed patient appointments rose 72% from 2,438 in Q4 2025 to 4,186 in Q1 2026. Myofunctional therapy visits increased 43% (from 337 in January to 481 in March). April saw the company’s highest ever 'Visit 2' conversion volume.
Operational Productivity Gains from Provider Training
Management highlighted substantial provider productivity improvements after retraining (example: a dentist improving from <$3,000/day to >$10,000/day; a peak day exceeding $40,000), indicating scalable per-provider revenue upside as experience grows.
Units Sold Increased Despite Revenue Mix Shift
The company sold 5,304 oral appliance arches and tooth positioners in Q1 2026 (units up ~42% versus 3,735 in Q1 2025), demonstrating volume strength even though product revenue declined due to discounts and product mix.
High-Potential Growth Initiatives
Management outlined initiatives expected to drive future revenue: pediatric program with net margins >60% and potential ~ $1M revenue per site (revenue expected to begin in July); insomnia diagnostic/treatment program (estimated $2,000–$3,000 incremental revenue per patient in year one); and affiliations with medical specialty groups (e.g., cardiologists) to expand referral volume.
Cost-Saving Measures Implemented
Company stated it has implemented cost savings measures intended to reduce cash used in operations while continuing integration of acquired operations.
VVOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VVOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 20, 2026 | $0.59 | $0.58 | -1.02% |
Apr 15, 2026 | $1.47 | $1.09 | -25.85% |
Nov 19, 2025 | $2.36 | $2.12 | -10.17% |
Aug 19, 2025 | $4.27 | $4.13 | -3.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vivos Therapeutics (VVOS) report earnings?
Vivos Therapeutics (VVOS) is schdueled to report earning on Aug 19, 2026, After Close (Confirmed).
What is Vivos Therapeutics (VVOS) earnings time?
Vivos Therapeutics (VVOS) earnings time is at Aug 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VVOS EPS forecast?
VVOS EPS forecast for the fiscal quarter 2026 (Q2) is -0.33.